Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,159,392
  • Shares Outstanding, K 956,450
  • Annual Sales, $ 22,320 M
  • Annual Income, $ 8,318 M
  • 60-Month Beta 0.24
  • Price/Sales 6.53
  • Price/Cash Flow 21.52
  • Price/Book 45.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 1.60
  • Number of Estimates 3
  • High Estimate 1.62
  • Low Estimate 1.56
  • Prior Year 1.50
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
143.62 +7.13%
on 05/27/20
162.37 -5.24%
on 05/18/20
+0.23 (+0.15%)
since 05/01/20
3-Month
117.06 +31.44%
on 03/23/20
164.90 -6.69%
on 04/24/20
+21.02 (+15.82%)
since 03/02/20
52-Week
101.36 +51.80%
on 10/23/19
164.90 -6.69%
on 04/24/20
+37.92 (+32.71%)
since 05/31/19

Most Recent Stories

More News
The Global Protein Therapeutics Market is expected to grow from USD 56,236.13 Million in 2018 to USD 91,756.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.24%

, /PRNewswire/ --The Global Protein Therapeutics Market is expected to grow from in 2018 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.24%. Read the full report: The positioning...

AMGN : 223.72 (-1.41%)
BAX : 90.98 (+0.65%)
LLY : 153.86 (+0.92%)
GNBT : 0.5400 (-8.47%)
NVO : 65.15 (-0.84%)
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy

Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.

JNJ : 148.25 (+0.72%)
SNY : 49.89 (+0.81%)
GILD : 73.26 (-2.53%)
LLY : 153.86 (+0.92%)
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates

Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19....

REGN : 617.66 (+3.03%)
PFE : 36.16 (+1.97%)
GILD : 73.26 (-2.53%)
MRNA : 59.87 (-3.72%)
LLY : 153.86 (+0.92%)
GSK : 42.03 (+0.43%)
VIR : 37.03 (+4.75%)
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4

NextGen's (NXGN) fiscal fourth-quarter 2020 results gain from strong Recurring revenues.

BIIB : 302.86 (+0.47%)
LLY : 153.86 (+0.92%)
NXGN : 10.48 (+1.85%)
APHA : 4.50 (+1.35%)
Psychedelic Drugs Could Potentially Treat Impending Post-lockdown Mental Health Epidemic

, /PRNewswire/ --  Trials are already underway testing the use of psychedelics such as psilocybin, LSD, ketamine, ecstasy and other currently scheduled drugs to predicted to hit after the lockdown...

JNJ : 148.25 (+0.72%)
SHRM.CN : 1.570 (-7.10%)
SHRMF : 1.1700 (-6.40%)
LLY : 153.86 (+0.92%)
NUMI.VN : 0.760 (unch)
LKYSD : 0.5500 (-2.38%)
MMEDF : 0.3811 (+0.29%)
BGHM : 0.4600 (+12.20%)
Animal Vaccines Market to Exhibit 6.4% CAGR by 2027; Government-imposed Regulations on Timely Animal Vaccination to Aid in Expansion of Market says Fortune Business Insights(TM)

The global Animal Vaccines Market size is projected to hit USD 16.01 billion by the end of 2026 attributed to the increasing awareness about animal diseases and the increasing importance of animal health...

LLY : 153.86 (+0.92%)
ICCC : 4.46 (+1.42%)
MRK : 80.84 (+1.61%)
NEOG : 71.27 (-0.78%)
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity

Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...

PFE : 36.16 (+1.97%)
MRK : 80.84 (+1.61%)
LLY : 153.86 (+0.92%)
VRTX : 284.27 (-0.83%)
ABBV : 91.04 (+0.37%)
CRSP : 68.36 (+2.66%)
Top Stock Picks for Week of June 1, 2020

Two Zacks Strong Buy Stocks in Focus.

BJ : 36.47 (-0.55%)
LLY : 153.86 (+0.92%)
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding

The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.

LLY : 153.86 (+0.92%)
NBIX : 123.37 (-0.02%)
ABBV : 91.04 (+0.37%)
INVA : 13.86 (-0.07%)
Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer

FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers....

AZN : 54.72 (-0.80%)
RHHBY : 43.8000 (+0.85%)
LLY : 153.86 (+0.92%)
ABBV : 91.04 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 156.03
1st Resistance Point 154.95
Last Price 153.86
1st Support Level 151.91
2nd Support Level 149.95

See More

52-Week High 164.90
Last Price 153.86
Fibonacci 61.8% 140.63
Fibonacci 50% 133.13
Fibonacci 38.2% 125.63
52-Week Low 101.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar